You are here

BioNTech

Heart Problem More Common After Covid-19 Than After Vaccination, Study Finds

Heart Problem More Common After Covid-19 Than After Vaccination, Study Finds

NY Times, NY

Flag link:

Did Pfizer's and BioNTech's FDA Submission Boost the Case for Booster Doses for All Americans?

Did Pfizer's and BioNTech's FDA Submission Boost the Case for Booster Doses for All Americans?

Motley Fool

Flag link:

FDA grants full approval to Covid-19 vaccine developed by Pfizer, BioNTech

FDA grants full approval to Covid-19 vaccine developed by Pfizer, BioNTech

Stat

Flag link:

The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday

The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday

NY Times, NY

Flag link:

Third Pfizer dose 86% effective in over 60s, Israeli HMO says

Third Pfizer dose 86% effective in over 60s, Israeli HMO says

Reuters

Delta COVID-19 variant

Flag link:

Pfizer, BioNTech file for FDA approval of COVID booster shot

Pfizer, BioNTech file for FDA approval of COVID booster shot

Pharmaforum

Flag link:

Pfizer and BioNTech COVID-19 vaccine capacity to hit 4 billion doses in 2022

Pfizer and BioNTech COVID-19 vaccine capacity to hit 4 billion doses in 2022

Biopharma Reporter

Flag link:

BioNTech, eyeing $18B+ in COVID-19 vaccine sales this year, poised to join the ranks of the world's top drugmakers

BioNTech, eyeing $18B+ in COVID-19 vaccine sales this year, poised to join the ranks of the world's top drugmakers

Fierce Pharma

Flag link:

Why COVID Vaccines for Younger Kids Won't Win Authorization as Soon as Expected

Why COVID Vaccines for Younger Kids Won't Win Authorization as Soon as Expected

Motley Fool

Moderna Therapeutics

Flag link:

Is BioNTech Contradicting Pfizer About the Need for Booster Doses?

Is BioNTech Contradicting Pfizer About the Need for Booster Doses?

Motley Fool

Flag link:

This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine

This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine

Motley Fool

clinical trials

Flag link:

Pfizer-BioNTech COVID-19 vaccine outperforms Sinovac jab in antibody study

Pfizer-BioNTech COVID-19 vaccine outperforms Sinovac jab in antibody study

Biopharma Reporter

Flag link:

Why Moderna and BioNTech Slipped Today

Why Moderna and BioNTech Slipped Today

Motley Fool

Moderna Therapeutics

Flag link:

AstraZeneca and mRNA COVID-19 vaccines ‘show similar safety profiles’

AstraZeneca and mRNA COVID-19 vaccines ‘show similar safety profiles’

Biopharma Reporter

Flag link:

BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

BioPharma Dive

Flag link:

Pfizer and BioNTech continue to add COVID-19 vaccine orders

Pfizer and BioNTech continue to add COVID-19 vaccine orders

Biopharma Reporter

Flag link:

Study finds vaccines cut severe variant COVID disease after one shot

Study finds vaccines cut severe variant COVID disease after one shot

Pharmaforum

real world evidence

Delta COVID-19 variant

Flag link:

The FDA may not fully approve a COVID-19 vaccine until January. Here’s why

The FDA may not fully approve a COVID-19 vaccine until January. Here’s why

Marketwatch

Flag link:

BioNTech returns to cancer roots with deal for Gilead cell therapy factory

BioNTech returns to cancer roots with deal for Gilead cell therapy factory

BioPharma Dive

Gilead Sciences

Flag link:

FDA grants priority review for Pfizer COVID-19 vaccine BLA

FDA grants priority review for Pfizer COVID-19 vaccine BLA

Biopharma Reporter

priority review

Flag link:

Pages